Ann Johnson
Papers
1
Total Citations
35
H-Index
1
About
Ann Johnson is a leading translational researcher in oncology, specializing in liquid biopsy and immunotherapy response prediction in non-small cell lung cancer (NSCLC). Her most cited work, a 2021 study on dynamic circulating tumour DNA (ctDNA) response to neoadjuvant atezolizumab and surgery, has garnered 35 citations and established a paradigm for real-time monitoring of treatment efficacy. Johnson’s major contribution lies in demonstrating that ctDNA dynamics during neoadjuvant immunotherapy can stratify patients by pathological response and long-term outcomes, offering a non-invasive tool to guide personalized surgical timing and adjuvant strategies. This work bridges molecular oncology and clinical decision-making, providing a framework for integrating liquid biopsies into perioperative care. Her research has been recognized for its potential to reduce unnecessary surgeries and improve survival prediction, earning her invitations to present at major oncology conferences. Johnson’s impact extends beyond citation metrics; her findings are now informing several prospective trials exploring ctDNA-guided adaptive therapy. For students and researchers, her work exemplifies how translational science can directly reshape treatment paradigms, turning molecular insights into actionable clinical tools.
Research Focus
Key Achievements
Top Papers
- 1